

References

- **Abi said D, Anaissie E, Lzun O. Raad I, Pinzcowsk H, Vartivarian S, (1997):** The eipidemiology of haematogenous candidiasis caused by different candida species. Clin Infect Dis:24: 122-1128.
- **Adrie C, Alberti C, Chaix-couturier C, Azoulay E, Delassence A, Cohen Y, Meshaka P, Cheval C, Thuong M, Troche G, Garrouste orgeas M, Timsit JF(2005):** Epidemiology and economic evaluation of severe sepsis in france J, crit care, 20:46-58.
- **Ahmed S, Khan Z, Mustafa A, and Khan ZU, (2002):** Seminested PCR for diagnosis of candidemia comparison with culture antigen detection and biochemical method for species identification journal of clinical microbiology ;6:2483-2489
- **Al Doory MS (1980):** systemic candidiasis and other fungal infections in the newborn, pediatric infect Dis ;5:35.
- **Aliff TB, Maslak PG, Jurcic JG(2003):** Refractory Aspergillums pneumonia in patients with acute leukemia successful therapy with combination caspofungin and liposomal amphotericin B. Cancer;97:1025-1032
- **Alonso V, Acha O, Garcia J, Alvarez C, Mazarrasa C, Fainas M,(2003):** Candidemia in a teretiary care hospital: epidemiology and factors, influencing mortality. Eur J Clin microbial Infect Dis. Apr; 22 (4):254-7.

- **Altamura M, Casale D, Pepe M, Tafaro A(2001):** Immune responses to fungal infections and therapeutic implications. *Curr Drug Targets Immune Endocr Metabol Disord*; 1 (3) : 189-97.
- **Aly R, Frney R, Alyes C.B.(2001):** Treatment for common superficial fungal infections *dermatol nurs* ,13(2):91-94,98-99
- **Arendrup, MC, Funrsted K, Gahrn - Hansen, B., Jensen, LM (2008):** seminal surveillance of fungemia Notably High Rates of fungemia and numbers of isolates with **reduced azole** susceptibility pp. 516-527.
- **Ascioglu S, Rex JH, de pau w B, Bennet JE, Bille J (2002):** Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplantations: an international consensus *clin infect DI*, 34 (1) : 7-14.
- **Badero M, Bow YF; (1996) :** Trends in antifungal susceptibility and epidemiology of nosocomial yeast infections in a university Hospital. *Jclin Microbiol*; 37: 431-437.
- **Baily GC, Moone CB, Essayag SM, De wit S, Barine JP, Denning DW (1997):** *Candida inconspicua*, fluconazole-resistant pathogen in patients infected with human immunodeficiency virus *clin Infect Dis*.:25:161.
- **Baley JE Kliegman RM, Boxerbaum B, Fanaroff AA(1986):** fungal colonization in the very low birth weight infant pediatrics; 78: 225-32.
- **Benjamin DK JE: Ross K; Mckinney RE JR, Auten R, Fisher RG (2000) :** When to suspect fungal infection in neonates: a clinical

comparison of candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia pediatrics, 106: 712-718.

- **Bennett JE (1998)** : Fungal Infections. In : Hamson's principles of internal medicine, 14th edn vol 1 ch. 202, P: 1148-1163. Fauci A-S., Braunwold E; Jsselbacher KA, et al., Eds. Mc Grow-Hill, New York.
- **Berronane, YF., Hemaldf LA, and Pfaller MA. (2007)**: Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital pp. 540-547.
- **Berrouane XF, Herwaldt LA, et al (1999)**: Antifungal use and epidemiology of noscomial candida infections in university hospital. J. Clin Microbiol; 37:531-537.
- **Bills SH, Xhag D, Gough D, Byum B, Cho(1998)**: Detection and differentiation of causative fungi of onychomycosis using PCR amplification and restriction enzyme analysis. Int JR. Dermatol ,37:682-686
- **Bodey GP (1993)**: Antifungal agents. In : Bodey G.P. (edr) : Candidiasis. P : 371. New York Raven press.
- **Botas CM, Kurhart I, et al (1995)**: Disseminated candidal infections an intravenous hydrocorhsone in pretern infants pediatnls.
- **Bow YF, HerwaldT LA, Pfaller MA(1999)**: Trends in antifungal susceptiblies and epidemiology of nosocomial infections in university hospital. J Clin micropbioa:27:231-237

- **Brenner GM(2000):** Antifungal drug, in pharma cology, 1st edn. Ch 42,p,441-447. W.B. saunders company, Philadelphia
- **Candoni A, Mestroni A, Damiani D, Tiribelli M, Michelutti A, Silvestri F, Castelli M, Viale P, Fanin R(2005):** Caspofing as first line therapy of pulomonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies Eur J Haematol, 75(3):227-233
- **Carpenter CHF and JR Maenza (2001) :** Candidiasis in: Current therapy of infect. Dis. , 2nd edn. P: 696-699. schools-berg D.edr. Mosby International limited, London.
- **Chaaib F, Queiroz EF, Ndjoko K, Diallo D, Hostettmann K, (2003):** Antifungal and antioxidant compounds from the root bark of fagara zanthoxyloides. Plants med Apr, 69 (4) : 316-320.
- **Chart F; Buchheidt D; Skladny H; Baustc; Hehlmann R (2002):** Systemic infections with Candida spp. and aspergilu, spp. in immuncompromised patients with hematological malignancies; 46 (4) : 219:229 (abstract).
- **Chumpitazi F, Buchheidt D, Sklodny H; (2000) :** Systemic infections with Candida spp. And Aspergillus spp. In immuncomprised patients with Haematological malignancies: 46 (3) : 219-228 (abstract).
- **Claudia Hartung DE capriles, Sofia M, Amparo A, Adriana P, Sylvia M, Celina P, Arantza R, Maria T, Miurpiology Department(2005):** Neonatat candidiasis in Venezuela: Clinical and epidiological aspects, 9:11:20.

- **Clemons KV, Calich VI, Burger E, Campa A et al.(2000):** pathogenesis. Interactions of host cells and fungi. Med. Mycol, 38-99-111.
- **Collin L, Sulliran DJ, Benett DE, Moran GP, Brry HJ(1999):** Candidiasis: the emergence of anovel species , candida dubiniensis. AIDS
- **Crislip MA and JE Edwards (1992) :** Candida albicans and related species in : Infections diseases 1st eden, ch. 283, P: 1887-1894. Gorbach SL., Bartllett J.G. and 13 lacklow N.R.edr., Saunders W.B. company, Philadelphia, Pennsylvania.
- **Darkes, MJ , Scott LJ, Goo KL(2003):** Terbinafine :a review of its use in onychomycosis in adults Am. J Clin dermatol ;4(1):39-65
- **Davis SL, Vuzquef, J.A, Mckinnon, P.S (2007):** Epidemiology, Risk factors, and outcome of Candida albicans versus Non-albicans candidemia in Nonneutropenic patients pp. 566-573.
- **Deepe JGS.(1997):** Prospects for the development of fungal vaccines clin Microbiol Rev. 10: 585-596.
- **Denning DW, Ribaud P, M Lpied N, Caillot D, Herbrecl D, Theiel E, Hass A, Ruhnke M Lode H (2003):** Efficacy and safety of voricononazol in treatment of acute invasive aspergillosis. Clin infect Dis ;34:564-65-71
- **DeVroey C, Desmet P, LIZQ ;Mukamurangwa P, Rues-Wuytack C(1996):** Further studies on the in vitro antifungal activity of amorolfine. Mycosis' 39:41-44
- **Diaxon DM, Rhodes SC, Fromnung RA (1999):** Taxonomy, Classification and morphlogh of the fung. In manual of Clin

Microbiol, 7th edn Ch.93,P:1161-1166. Murray P.R., Baron E.J. and pfaller MA edr. ASM, Washington DC.

- **Dickema J, Messer L, Boyken N(2008):** Activities of fulconazole and voriconazole against recent clinical isolates of candida species Determined by broth micro dilution ,Disk diffusion , and E. test methods ,J clin microbial 36:3429-3432.
- **Doonquah L, Dalapenha R,peters B,peoples D, Mcneilj, Frederick WR.(1997):** Fungemia in intensive care unit (ICU) patients, Abstract no .149, Abstracts of DSA ISDA 35th Annual meeting Cline Infect Dis;25:383.
- **Edman JC (1995):** Medical Mycology In : Medical Microbiology. 20th edn. Ch. 45, P: 555-556. Brook GF. Butel J.S., and omston LN edr. Copy right by Appleton & lange.
- **Edmond, M.B., S.E. Wallace, D.K Modish, M.A. Pfaller, RM Jorpsf and R.D wenzed. (2008)** Nosocomial blood streem infections in united states hospital pp. 230-244.
- **El Farsy M, (2007):** Early Diagnosis of fungal infection in neonates in thesis pediatric Mohamed G, Shafik S and Abdou S. Faculty Of Medicine Ain Shams University.
- **Elie CM , Lott TJ, Reiss E, and Morrison CJ(2002):** Rabid identification of candida species with specific DNA probes journal of clinical microbial; 36 (11)3260-3265
- **Eliwa M,(2007):** Nosocomial Infections in Neonatal Intensive care unit of obstetrics and Gynecology Hospital, Incidence and risk factors in thesis pediatric Mamdouh M, Maha M., Hala M. Faculty Of Medicine Ain Shams University

- ***El-Mohandes AE, Johnson-Rubbins L; Keiser JF, Simens SH, Aure MV (1994):*** Incidence of candida parpasilosis colonization in an intensive care nursery population and its association with intensive fungal disease pediatric Infections disease Journal, 31: 520-4.
- ***El-sadek F, Prof. Dr. M. El –Alfy , Prof DR Nancy Soliman, Prof Dr E. Kamel, Dr Eman(2007):*** faculty of medicine Ain shams University: Platelet count and sepsis in low Birth weight Neonates.
- ***Espinel A and Pfaller M (1992):*** Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests J clin microbial; 30(10) : 3138-3145.
- ***Espinel A, Ingroff M, Ryder NS (1995):*** Antifungal susceptibility test by different method, clin Micrbiol; 40 (10) :3138-3149.
- ***Espinel A, White TH, P faller MA (1999):*** Antifungal agenst and susceptibility tests. In : Manual of din. Microbiol., 7th edn ch .126, P:1640-1652. Murray PR, Baron EJ, P fallor MA edn, ASM, Washington DC.
- ***Espinel- Ingroff, A.L. Steel –moore, and J.N. Galgini (1994):*** Evaluation of 80% inhibition standards for demermination of 80% inhibition standards for determination of fluconazole minimum inhibition concentrations in three laboratories. Diagn. Microbiol .Infect. Dis.20:81-86.
- ***Faix M(1992):*** candida species. In: principles and practice of infect. Dis. 3rd edr p: 2289-2305.
- ***Faix RG (1992):*** Invasive neonatal candidasis: Comparison of albicans and parpsilosis infection. Pediatric infect dis J.

- **Favre B and Ryder NS(1996):** Characterization of squalene epoxidase activity from the dermatophyte terbinafine and other antimycotic agents. *Antimicrob. Ag. Chemoth* 30:443-447
- **Ferrari FA, Pagani A, Marconi M, et al.(1971):** inhibition of candidal activity of human neutrophil leukocytes by aminoglycoside antibiotics. *Antimicrob Agents chemother.*
- **Fidel PL JR, Vazquez JA, and Sobel J(2002):** Distinct protective host defenses against oral and vaginal candidiasis. *Med Mycol.* Aug; 40 (4) : 359-57.
- **Fisher JF and Cook NB (1998):** Yeasts and Yeast like organisms. In: *Fundaamentals of Diagnostic mycology* 1st edn, Ch.7, p:196-230 WB sanders company , Philadelphia, London, Toronto.
- **Forsgren A, Schmeling D, Quie PG.(1974):** effect of tetracycline on the phagocytic function of human leukocytes. *J Infect Dis.*; 130: 412-415.
- **Frank U, Malkotis D , Mlangeni D et al(1999):** Controlled clinical compassion of three commercial blood culture systems. *Eur J Clin Microbial infect Dis* 18: 248-55
- **Garcia R. Cabello R, Cruz F, Bonifaz A, Marquez F,(2002):** Study on *Candida non-albicma* species and its relation to recurrent Vulvovaginal candidiasis. *Ginecol obstet mex.* 2002 sep; 70;431-6.
- **Garczewska B, Dzierzanowska D(2002):** Use of molecular biology method for diagnosis of fungal infections *med Dosw Microbiol*; 54(2):157-65

- **Garro M, Henart H, Laffler J, Reitze H, Engel A, , Schumacher V, Klugebiel T (2000):** Prospective screening by panfungal polymerase chain reaction assay in patients at risk for fungal infection Br J Haemaol;111:635-640
- **Gill VJ, Fedorko DP, and Witebsky FG(2000):** The clinician and the microbiology laboratory. In : mandell GL, Dolin R, Bennett JF, editions principles and practices of infections diseases Philadelphia (PA) : Churchill –Livingston 184-221
- **Gillepie SH and Bamford KB(2000):** Yeast infections in : medical microbiology and infection at a glance 1st edn. Ch 32 p:70-71. black well science limited London
- **Girmeria S, Walsh TJ(1996):** Risk factors for fungal infection in neonates. Clin Int Dis: 18:525-532.
- **Glasmacher A, Prentice A, Gorschluter M(2003):** Itraconazole prevents invasive fungal infections in neutropenic a patients treated for hematological malignancies: evidence from a meta-analysis of 3, 597 patients. J Clin Oncol:21:4615-4626
- **Gomaa M, prof Dr Hisham A, prof Dr Afaf sh, Dr saffaa I, faculty of Medicine –Ain shams university(2004):** Candida colonization In neonatal Intestine care unit patients Receiving systemic antibiotics.
- **Groll AH and Walsh TJ(2001):** Caspofungin: pharmacology, safety and therapeutic pontential in superficial and invasive fungal infections. Expert opin investiy Drugs;10:1545-1558
- **Guaro and Gene S (1995):** Risk factors for fungal infection in neonates. Clin Int Dis; 18:525-532

- **Gudlaugsson M, Bamford RB (2003).** Yeast infections in : Medical microbiology and infections at a glance, 1st edn. Ch 32. p : 70-71. Black well science limited, London.
- **Gulay Z and Amir T.(1996):** Anti-Candidal activity of natural killer and lymphokine activated killer lymphocytes in vitro. Immunobiology. 195; 220-230.
- **Hay RL (1996):** Yeast infection. Cutaneous mycology Dermatology clinics; 14 : 113-124.
- **Hazen KC and Howell SA (2003) :** Candida , Cryptococcus and other yeasts of medical importance. In Manual of clinical importance. In : Manual of clinical microbiology 8th edn. Ch. 114, P 1693-1711. Murray PR; Baront and Pfuller MA, eds. ASM, Washington DC.
- **Hazen KC.(1999):** New and emerging yeast pathogens. Clin Microbiol Rev; 56 : 1462-1478.
- **Herbrecht R, Denning DW, Patterson RF(2002):** Voriconazole versus amphotericin B for primary therapy invasive aspergillosis N Engl J ,Med 347:408-415
- **Hovi YF, Herwaldt LA, Pfaller MA (2000):** Treatment and epidemiology of nosocomial yeast infections in an university Hospital. J Clin Microbiol; 7: 631-637.
- **Hoy SF (1998):** Antifungal drugs. In: the use of antibiotics .A clinical review of antibacterial, antifungal and antiviral Drugs 5th edn. Ch 4, P:1245-15-5 Kucers A, Crowe SM, Grayson ML and Hoy JF edr, Butterworth Heinemann.

- **Huang Y-C, Ylin T and Peng H.L et al (2007):** Outbreak of *Candida albicans* fungaemia in neonatal ICU, SC and J infect Dis 30, pp. 137-142.
- **Hurst S, Girmenia C, Nuzzi M, Martino P (2000):** Clinical significance of *aspergillus* fungemia in patients with hematologic malignancies. B, J Haematol, 111 : 634-635.
- **Iwasaki H, Misaki H, Nakamara T et al.,(2001):** Surveillance of the serum *candida* antigen titre for initiation of antifungal therapy after post remission chemotherapy in patients with acute leukemia (Int) Hematol ;71:266-72
- **Jabra- Rizk MA, Falkler JRW; Merz WG (2000):** Retrospective identification and characterization of *candida dubliniensis* isolates among *C-albicans* clinical laboratory isolated from human immunodeficiency virus (HIV) infected and non- HIV infected individuals J- clin microbial, 38 (6): 2423-2426.
- **Jarvis WR, Carroll NM, Choudhury S(1996):** The epidemiology of colonization. Infect control Hosp Epidemiol.
- **Jeffrey B, Campbell F, Glen Seidel, Ejdmocl T, Gonzales TR (2004):**Use of a mechanical thrombectomy catheter for percutaneous extraction of renal fungal bezoars in apremature infants, 589e6 : 589 e8.
- **Johnson MD, MacDougall C, Ostrosky-Zechner L(2004):** Combination antifungal therapy. Antimicrob agents chemother; 48:693-715
- **Kaiserova E,krcmry V JR.(1898):** Fungemia in children with cancer. Pediatr infect Dis J: 19:844-845.

- **Kami MU; Mecida K; Dkuzmi T; Matusmura T; Mori S (2002):** Effect of fluconazole prophylaxis on fungal blood cultures. Br J Haematol; 117 (1) : 40-46.
- **kirkpatric WR, Turner TM, Fothergill AW, Mc Coaurhty Di, Redding SW, Patterson RF (2000) :** Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol; 36 (11) : 3429-3432.
- **Kontoyuannis DP, Hachem R, Lewis RF(2003):** Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B primary or salvage treatment of invasive aspergillosis in patients with hematology ,malignancies cancer 98:292-299
- **Krcmery S (2001) :** usual and unusual risk factors of infection in cancer patients. 11th European congress of clin. Microbiol and infect. Dis. Istanbul; Turkey, P: 37 (Congress abstract book).
- **Krcmery V JR, Kunova A(2000):** candida famata fungemia in a cancer patient:case report. J chemother:12:189:190.
- **Krcmery V JR.(1999):** Candiedemia in cancer patients: Risk Factors and outcome in 140 episodes from a single cancer institution. Acta chemoth; 5: 133-145.
- **Krcrney S, Dubrava M, Krcmery VJ (1999):** Fungal Urinary tract infections in patients risk. Int J Antimicrob Agents. (3): 389-391.
- **Kuhn DM, Chandra J, Mukherjee PK, and Ghannoum MA (2002):** comparison of biofilms formed by Candida Albican and candida parapsilosis on bioprosthetic surfaces. Infection and Immunity; 70(2):878-888.

- **Kusene S and Shapiro M(1998):** Invasive yeast infections other than candida Spp. In : acute leukemia. Hosp infect ;41(3):181-194
- **Kwonchung KJ and Bennett JE(1992):** Candidiasis. In :medical mycol ;p280-337. an febiger philadelphia
- **Lee SJ, Zheng NY, Clavijom, Nussenzweig MC(2003):** Normal host defense during systemic candidiasis. Infect Immune. Jan; 71 (1) : 437-45.
- **Leequaglie CG, Basilico M, Massone PB(1998):** Lyposomal antifungal therapy and low toxicity in thoracic cancer patients in ICU 8th international congerss of infect. Dis bostron Massachausetts, USA p:96(congress abstract book)
- **Leibovitz E, Luster- Reicher A, Amitai M, Mogilner P(2006):** Neanatal candidiasis: clinical picture , management controversies and consensus, and new therabeutic options, 49:69-73.
- **Lenderman MM (2001):** Infections of urinary tract in: Andereoli Cecil essential of medicine, 5th edn. Ch. 105. P: 825-827. Carpenters Company, Philadelphia.
- **Lethrer RI.(1971):** Inhibition by sulphonamides of the candida activity of human neutrophils. J Clin Invest; 90: 2498-2505
- **Levey J, Shalit I, Birk E Sirota L, Askenazo S, German B, Linder N(2006):** candida endocarditis in neonates: report of five cases and review of the literature mycosis,.
- **Levy I, Rubin LG, Vasishtha S, Tucciv, Sood KS.(1998):** Emergence of Candida Parpsilosis as the predominant species causing candidemia in children. Clin Infect Dis:26:1056-1088.

- **Linares M, Swall D, Barry S (1998):** comparison of broth microdilution broth microdiution and E test antifungal susceptibility tests for fluconazole J. Clin microbial. 32:2099:2102.
- **Linda M, Beak SH, Hecker H(2000):** Detection and differentiation of causative fungi of onychomycosis using PCR complification and restriction enzyme analysis. Int. Jr. Dermatol; 37:682-686.
- **Long p(2003):** Principles and Practice of Pediatric infections diseases 2nd ed .
- **Lopez SN, Coworkers S, Sortino M, Correa R, Decompos F (2003):** Antifungal properties of novel N- alpha, beta and beta substituted succinimides against dermatophytes. Arzneimittel-forschung; 53 (4) :280-228 (abstract).
- **Mackenzie PH (1962):** Indentification of different candida species .Mycosis; 45 (1-2) :22:28.
- **Maertens J and Boogaerts M (2005):** The place for Itraconazole in treatment. J Antimicrob chemother; 56 suppl; 1 : 133-138.
- **Makhoul RI, Kassis I, Smolkin T, Tamir A, Snjor P(2001):** Review of 49 neonates with acquired fungal sepsis: further characterization. Pediatrics.
- **Manzoni P, Arisio R, Mostent M, Leonessa M, Farina D, Agnes M, et al. (2006):** Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates, 22:32.
- **Marcon S, Dawell T(1992):** Acquired fungal sepsis :Further charator zation pediatric :20:107

- **Marot N, Leblond S, Linda M(2004):** Diagnosis of candidiasis in patients of intensive care units. *Pediatrics* ,78;225-32
- **Marr K, Crippuf, Leisenring W(2004):** Itraconazol versus fluconazole for prevention of fungal infections in patients receiving allogenic stem cell transplant. *Blood* :103:1529-1533
- **Mayer F, Magadia R, Weinsterin P(2004):** Laboratory diagnosis of bacteremia and fungemia. *Clin infect dis* ;15(4)L1009-24
- **Mccultiotgh BP, Keating C, Cuman MD, Mcmullin MF (1999):** Identification of medically important pathogenic fungi reference strand-mediated conformational analysis. *J med microbial.*, 51(6):468-478.
- **McEwen JG, Taylor JW, Carter D et al(2000):** Molecular typing of fungi. *Med mycol* :83(suppl 1):189-97
- **Mendiratta DK, Rawat V, Thamke D, Chaturvedi P, chhabra S (2006):** Department of microbiology; Deepartment of pediatrics, Department of obstetric, India: candida colonization in preterm babies admitted to neonatal intensive care unit, 4:263-267.
- **Mermel LA, Farr BM, Sheretz RJ, Raad II, D, Grady N, Harris and craven DE.(2001):** Guidelines for the management of intravascular catheter-related infections. *Clin. Infect. Dis*:32:1249-1272.
- **Morace G, pagano L; Saguinettim M, Posteraro B, Mele L, et al.,(1999):** PCR restriction enzyme analysis for detection of candida DNA in blood from febrile patients with hematological malignancies. *Clin microbial* ;37(6):1871-1875.

- **Moran S, Sanguinetti B, Posteraro EL, Fadda G(1998):** identification of various medically important *Candida* species in clinical specimens by PCR- Restriction enzyme analysis. *J Clin microbial*; 35:667-672
- **Narang A, Agraeul P, Chakrabort A, Kumar P(1998):** Fluconazole in the management of neonatal systemic candidiasis. *Ind pediatric*.
- **National Committee for Clinical Laboratory Standards (1995):** methods for antifungal susceptibility testing of yeasts: proposed guideline m 44-p . National committee for clinical laboratory standards. Wayne, pa.
- **Nguyen MH; Peacock JE, JR; Morris AJ. Tanner dc (1996):** The change in face of candidemia: emergence of non-*Candida albicans* species and antifungal resistances. *Am J Med*: 100 (6) : 617-23
- **Niewerth , Kortling H (2002):** *Candida Albicans* and the principle of opportunism. An essay. *Mycoses*. Oct;45(8):253-8.
- **Noskin G. Coffey G, Gurwith M.(1996):** treatment of candidemia with amphotericin B colloidal dispersion. Abstract No. 75, abstracts of the IDSA 34th Annual meeting. *Clin Infect Dis*:23:874.
- **Odds FC (1988):** *Candida and candidiasis*, 2nd edn, London bailliere, Tindall.
- **O'shaughnessy E, Shea Y, Witebsky G(2003):** Laboratory diagnosis of invasive mycoses. *Infections disease clinical of north America*.17(1):135-58

- **Pangano L; Caira M; Fianch L (2005):** Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. *Ann med*;37(4)259-269
- **Pappas PG, Rex JH, et al (2003):** A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. *Clin infect Dis*.
- **Pappas PG, Rex JH, Sobel JD(2004):** Guidelines for treatment of candidiasis, *Clin infect disease*, 38:161-189.
- **peman J, Caton E, Orero A, Viudes A, Farsquet J.(2002):** Multicenter M: Epidemiology of Candedemia in spain Multicenter study *Reviberoam Micol Mar*, 19 (1): 30-35.
- **Perfect C and Schell M (1996):** Fluconazole resistant pathogen in patients infected with human immunodeficiency virus. *Clin infect dis*; 25:161
- **Persons SH (1999):** Fungal infection in neonates, comparison between candida albicans and non albicans species distribution *pediatrics*; 106:712-718.
- **Pfaller MA and Diekema DJ(2004):** Twelve years of fluconazol susceptibility of blood stream isolates of candida *clin microbial Infect*.
- **Pfaller MA, Diekema DJ, et al (2002):** Trends in antifungal susceptibility of candida spp. Isolated from pediatric and adult patients with blood stream infections: SENTRY Antimicrobial surveillance program.

- **Pfaller MA, Houston A, Coffman S(2001):** Application of chromagar for rapid screening of clinical specimens of candida tropicalis, candida krusei candida dubliniensis and candida glabrata. J Clin microbial 94:358-361
- **Pfaller MA, Messer SA, Kanisssn A, Bolmstrom A(1999):** Evaluation of the E test for determining fluconazole susceptibilities of 402 clinical isolates by using three different agar media. J Clin microbial ,36(9):2586-2589
- **Pfaller MA, S.A Messer, Ami A. Bolmstorm. (2006):** Evaluation "ofE test for determining in vitro susceptibility of yeast isolates to amphotericin B. Diugn, microbial infect. Dis 33: 223-227.
- **Pfaller MA., L Burmeister, M.A. Bartlett and M.G. Rinaldi (1988):** Multicenter evaluation of four methods of yeast inoculum preparation. J. Clin Microbiol. 26:1437-1441.
- **Rabkin A, Tionoudaki M, Petrodiu E(2000):** Fungemia and resistance to antifungal agents in a children's hospital 11th European congress of clinical microbiology and infection diseases. Istanbul, Turkey. P 170(congress abstract book)
- **Rang HP, Dale MM, Ritter JM(2000):** Antifungal drugs in :pharmacology, 4th ed. Ch 45,p:720-724 churchill living stone, London
- **Redding S., Dongarl-Bagtzolo UF, Barchies IF. (2008);** Candida glaberata, an Emerging oral opportunistic pathogen **pp.** 204-2151
- **Reiss E, Tanaka K, Bruker G et al(1998):** Molecular diagnosis and epidemiology of fungal infections med mycol :36(suppl 1) 249-57

- **Reiss E, Tanaka K, Obayashi T, Orle K , (2000):** Non-culture based diagnostic test for mycotic infections med mycol ;38(suppl 1):147-59
- **Rex H, Pappas PG, Karchmer AW(2003):** A randomized and blinded multicenter trials of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non neutropenic subjects . clin infect Dis, 36:1221-1228
- **Rex JH, M.G Rinaldi , and M.A. pfaller.(1995):** Resistance of candida species to fluconazole antimicrob .Agents chemother.39:1-8.
- **Rex JH, Wlash JT, Subel JD, Filler SG, pappas PG, Dismulces WE, Edwards JE(2000):** Practice guidelines for treatment of candidiasis. Infections diseases society of America. Clin infect Dis ;30:662-678
- **Rippon JW (2000):** Medical mycology 10 th edition W.B Saunders Co, Philadelphia USA
- **Ritter JM, Lweis LD, Mant TGK(1999):** Fungal and viral infections. In textbook of clinical pharmacology 4th edn. Ch 44,p 504-519. Arnold London
- **Rodriguez- tudela, JL, and JV. Martinez – suarez (1994):** Improved medium for fluconazole susceptibility testing of candida albicans . Antimicrob. Agents chemother. 38:45-48.
- **Rplston, Body M(1997):** Intravascular devices as a risk factor for candidiasis in neonatal Intensive care units,

- **Ryan KJ (1994):** Candida, Aspergillus, and other opportunistic fungi. In *Medical Microbiology: An introduction to infectious diseases*, 3rd ed. Kenneth J Ryan KJ edr. Copyright by Appleton and Lange.
- **Ryder NS(1999):** Activity of terbinafine against serious fungal pathogens. *Mycosis*;42:115-119
- **Saiman L, Ludington E, Dawson JD(2001):** Risk factors for candida species colonization of neonatal intensive care unit patients. *Pediatric infection Dis J*.
- **Saiman L, Ludington E, P Faller M.(2000):** Risk factors for candidemia in NICU patients. The national epidemiology of mycosis survey study group. *Pediatric infection Dis J*.
- **Samonis G, Daission M, Anastassiadou H:** Antibiotics affecting gastrointestinal colonization of mice by yeasts (1994).
- **Sandven P, Nislen K, Digranse A, Tjade T, Lassen J,(1997):** Candida no revegensies: afluconazole-resistant species. *Antimicrob Agents chemother*:41:1375-1376.
- **Sanglard D and Bille J(2002):** Current understanding of the modes of action and resistance mechanisms to conventional and emerging antifungal agents for the treatment of candida infection. In *candida and candidiasis*, ed. Richanal a, ASM press Washington ,DC
- **Sanglard D and odds FC (2002):** Resistance of candida species to antifungal agents: molecular mechanisms and clinical consequences. *Lancet infect Dis* , 2(2):73-85.

- **Saxen H, Virtanen M, et al (1995):** Neonatal candidal parapsilosis outbreak with a high case fatality rate. *Pediatr Infect Dis J*.
- **Segal E and Elad D (1998):** *Candida* species and *Blastochytrium capitatus*. In : Topley Wilson's Microbiology and Microbial Infections. 9th edn vol.4, ch 23, p:423-451. Collier L, Balows A and Summan M, eds Arnold, London, Sydney.
- **Selverange M, Posteraro B, Paano L, Pagliavi G, Mele L, La Sorda M, Franco A, Fadda G(2003):** Comparison of real time PCR, conventional PCR and galactomannan antigen detection by enzyme-linked immunosorbent assay using broncho-alveolar lavage fluid samples from hematology patients for diagnosis of Invasive pulmonary aspergillosis. *J Clin Microbiol*, 41 : 3922-3925.
- **Sendid B, Jabouret M, Poiprot JL, Bonnin A, Caillot D, Poulion D (2003) :** Combined detection of candidemia and antimannan antibodies as caused by pathogenic *Candida* species. *J Med Microbiol*; 51 (5) : 433-447.
- **Sheehan DJ., C.A. Hitchcock, and CM. Sibley (2007):** current and emerging azoles antifungal agents. *Clin microbial Rew*. 12: 40-79.
- **Sheehan S, Kassis I, Lusky A,(1999):** Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates; 32-42.
- **Shellow WVR(2000):** Management of superficial fungal infections. In primary care medicine office evaluation and 1049. Goroll AH and Murrel AG, eds Lippincott Williams and Wilkins Philadelphia

- **Sherertz. RJ, Gledhill Ks and Hampton KD et al.,(2006):** Outbreak of Candida blood stream infections associated with retrograde medication administration in a neonatal intensive care unit, J pediatr 120 pp. 455-461.
- **Shimokawa D and Nakymal H(2000):** Estimation of minimum sterol 14 demethylation –inhibitory concentration of azoles in candida yeasts using acetate medium growth inhibition: potential utility in susceptibility testing. J clin Microbiol ,38(8):2893-2896
- **Sigurgeirsson G, Christensson B, Bkorklund LJ (2002):** Long-term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis: a 5 years blinded prospective follow up study. Arch dermatology mar ;138(3):353-357.
- **Sobel JD (2001):** Candiduria In: Current therapy infectious diseases, 2nd edn. P: 234-235 Scgolssbrg, edr. Mosby International limited, London.
- **Solomon SL, Alexander H and Ley E et al.,(2007):** Nosocomial fungaemia in neonates associated with intravascular pressure monitoring devices, pediatr infect Dis J 5, pp. 680-685.
- **Sovova M and Sova P(2003):** Pharmaceutical significance of allium sativum L4 antifungal activity ceska slov farm Mar;52(2):82-87.
- **Spicer WJ (2000):** Specific pathogens: Fungi, Aspergillus and Candida . In: Clinical bacteriology, mycology and parasitology, 1st edn. P: 62-70. Churchill Livingstone, London.
- **Sqilkin F and Hurd A(1982):** Opportunistic mycoses. In : Zinsser microbiology, 20th edn ,h85;p:1135-1157

- **Stevens D(2002)** : Diagnosis of fungal infections currents status .
journal of antimicrobial chemotheraby:49,Suppl, 51, 11-19
- **Stevens M (2000):** Diagnosis of fungal infection in leukemia curr
oncol Rep; 3 (3) : 201-208.
- **Sufliarsky J, Sorkovska D, Kuniva A, Helpianskal, Krcmery V JR.(1998):** Break through fungemia caused by Candida stellatoidea in a patient with lymphoma associated with shock, successfully treated lymphoma associated with shock, successfully treated with amphotercin B lipid complex. Infection:59:1246-1247.
- **Sugar AM, Stevens DA. (1985):**Candida rugosa in immunocompromised cancer patients. Cases reports, drug susceptibility and review of the literature. Cancer;56:318:320.
- **Theoktis E. Zaoutis, Elyse foraker, Karinl, Me Gowan, Joel Mortensen, Joseph Campos, Thomas J, Walsh, Joel D (2005):** Antifungal sunscptibility of candida SPP. Isolated from pediatric patients.
- **Trick WE; Fridkin SK; Edwards JR, Hajjeh RA; Gaynes RP (2002):** Secular trend of hospital acquired candidemia among intensive care unit patients in united states during 1989-1999; Clin Infect Dis, 35: 627-630.
- **Vecente MF, Bassilio A, Cabello A, Pelaez F, (2003):** Microbial natural products as a source of antifungal clin microbio Infect; 9(1) : 15-32.
- **Vincent JL, Sakr Y, Sprung Cl, Ranieri VM, Gerlach H, Moreno R, Carlet J, LeGall Jr, Payen D(2006):** sepsis in European

intensive care units: results of the SDAP study. Crit care med.34:344-353.

- **Viscoli C, Girmenia C, Marinus A, et al.,(1999):** Invasive fungal Infection Group of the European organization for Research and treatment of cancer. Candidemia in cancer patient. A prospective, multicenter Surveillance study by the invasive fungal Infection Group (IFIG) of the European organization for research and Treatment of cancer (EORTC). Clin Infect Dis ;28: 1071-1079.
- **Wahyningsih R, Freislebon HJ, Sonntag HG, Schuitzer P (2000):** Simple and rapid detection of C.albicans DNA in serum by PCR for diagnosis of invasive Candidiasis. J clin microbial: 38 (8) : 3016-3021.
- **Walsh TJ, Ganzalez CE, Piscitelli S(2000):** correlation between in vitro and vivo antifungal activities in experimental fluconazole resistant oropharyngeal and esophageal candidiasis J clin microbial 38 (6) :2369-2373.
- **Walsh TJ, Sable C, Depauw B(2003):** A randomized, double blind multicenter trial of caspofunginvs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients (abstracts MI 761). In : program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy (chicago) Washington, DC American soctety for microbiology
- **Walsh TL and Pizzo A(1998):** treatment of systemic fungul infection: recent progress and current problems, Eur J clin Micro boil: 7(3):460-475.

- **Walter S, Coffee CC(1988):** Candida, Cryptococcus and other fungi of medical importance. In manual of clinical microbiology 5th edition ch.95P: 1881-1986
- **Warrn NG and Hazen KC (1999) :** Candiada, cryptococcus and other yeasts of medical importance in : Manual of clinical Microbiology 7th edn ch. 95. P: 1884-1199. Murray PR, Baeon EJ and Pfaller MA edr. ASM, Washington D.C.
- **Weems JSD.(1992):** Fetal and neonatal adrenocortical physiology. In :polin RA, fox WW, eds. Fetal and Neonatal physiology. Philadelphia: WB saunders: 2:1829-1841.
- **Wilson J (2000):** A guide to fungi. Protozoa, helminthes and ectoparasites. In Clinical microbiology: an introduction for health care professionals, 8th edn. Ch 10, p: 210-239.e Tindall, London.
- **Wingard JR, merz wG, et al (1991):** Increase in candida krusi infection among patients with bone marrow transplantation and neutropenia treated prophylactically With fluconazol.
- **Wingard JR(1995):** Importance of Candida species other than C.albicans as pathogens in oncology patients. Clin infect Dis ;20(1):115-125
- **Wingard JR(2004):** Empirical antifungal therapy in treating febrile neutropenic patients. Clin infect Dis,39(1):538-543
- **Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenbarger P, Woods G(2006):** Mycology in : Komeman's color atals and textbook of diagnostic microbiology. 6th ed, lippincott Williams and wikins

- **Winston DJ, Maziarz RT, Chandraseekar PH (2003):** Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem – cell transplant recipients: a multicenter, randomized trial. *Ann Intern Med* ;138(9):705-713
- **Winter JSD(1992):** Fetal and neonatal adrenocortical physiology .In : polin RA, Fox WW, eds. *Fetal and neonatal physiology*, Philadelphia.
- **Wu F ,Della –Latata P(2002):** Molecular typing strategies in neonatal perinatology. *Oct* ;26(5):357-66
- **Yuen C; Dick SD, Bosengard BR (1997):** Fetal disseminated candidiasis. *Ann Intern Med*; 102: 67-68.
- **Zaas AK, Dicks SD, Iwama A(2005):** Role in antifungal therapy: expert opinion *Pharmacother*; 6(20):1647-1668
- **Zaugg C, Zepelin MB, Reichard U, Saglard D, and Monod M .(2001):** secreted Aspartic proteinase family of *Candida tropicalis* infection and immunity;69(1):405-412.
- **Zhang MX, and Kozel TR.(1998):** Mannan – specific immunoglobulin G antibodies in normal human serum accelerate binding of C₃ to *Candida albicans* via the alternative complement pathway. *Infect. Immune*. 66: 4845-4850
- **Zu S and Alexander BD (2000):** Echinocandin role in antifungal therapy: expert opinion *Pharmacother* ;6(10):1657-1668
- **Zupanic-Krmek D; Nemet D; Mrcic M; Bogdanic V; Labor B; Jandrlic M; Kalenic S (2004):** Risk factors for invasive fungal infections during intensive chemotherapy of acute leukemia – retrospective study. (ABSTRACT) *Acta Med Croatica*; 58 (4): 275-284.